Nexentis Technologies Inc
NASDAQ:NXTS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NXTS's latest stock split occurred on Apr 8, 2026
The company executed a 1-for-7 stock split, meaning that for every 7 shares held, investors received 1 new share.
Before the split, NXTS traded at 0.5983 per share. Afterward, the share price was about 3.71.
The adjusted shares began trading on Apr 8, 2026. This was NXTS's 5th stock split, following the previous one in Sep 22, 2025.
Global
Stock Splits Monitor
Nexentis Technologies Inc
Glance View
N2OFF, Inc. is a cleantech company mainly engaged in European Union (EU) based solar assets using the Ready to Build (RTB) business model. The Company is an investor in four solar projects in three different EU countries. It collaborates with Solterra Renewable Energy Ltd., an Israeli corporation and a wholly owned subsidiary of Solterra Energy Ltd., an Israeli corporation, which operates in the solar energy sector and presents certain investment opportunities in solar photovoltaic (PV) projects. The Company also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatments in fruit and vegetables to control and prevent pathogen contamination. The Company’s solutions are focused on improving the food safety and shelf life of fresh produce. The Company, through its subsidiary, MitoCareX Bio Ltd., is focused on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family.
7739
ANAB
CNTM